This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
GLP-1 receptor agonists reduced pancreatic beta cell death by about 10 percentage points in preclinical models, supporting the idea that these drugs help preserve insulin-producing cells.
Why it matters
Diabetes involves the gradual loss of beta cells that make insulin. If GLP-1 drugs can slow this loss, they may do more than just control blood sugar. They could help protect the pancreas itself.
The numbers in context
Pooled mean difference in apoptosis: -0.10 (95% CI -0.15 to -0.05, p = 0.0003). 5 studies included. I-squared = 100% (extreme heterogeneity). Egger's test p = 0.80 (no publication bias detected).
How the study worked
Systematic review and meta-analysis following PRISMA guidelines. Searched Scopus, PubMed, Embase, and Google Scholar. Included preclinical studies of GLP-1 RA effects on human beta cell apoptosis. Random-effects model.
Who was studied
Human pancreatic beta cells in laboratory culture (preclinical)
What this study cannot tell us
Only five studies met criteria. Extreme heterogeneity (I-squared = 100%) limits confidence in the pooled estimate. All preclinical data from cell cultures. No human clinical evidence. Long-term effects on beta cell function unknown.
Read the original research
GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.
Frontiers in clinical diabetes and healthcare, 6, 1579961
Citation
Rea, Nicolas; Ramdass, Prakash V A K. (2025). GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus: a systematic review and meta-analysis of preclinical studies.. Frontiers in clinical diabetes and healthcare, 6, 1579961. https://doi.org/10.3389/fcdhc.2025.1579961